PubRank

W A Schleif

Author PubWeight™ 90.68‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988 10.77
2 In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995 10.13
3 Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991 7.01
4 Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992 4.75
5 Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996 4.45
6 Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992 3.85
7 L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994 3.00
8 A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med 1993 2.98
9 Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A 1991 2.67
10 Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990 2.65
11 Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000 2.10
12 Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother 1993 2.10
13 L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994 2.07
14 The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996 2.04
15 Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol 1986 1.68
16 Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998 1.59
17 Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother 1994 1.53
18 HIV and multidrug resistance. Nature 1993 1.31
19 A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J Virol Methods 1988 1.31
20 Inhibition of human immunodeficiency virus-1 reverse transcriptase activity by rubromycins: competitive interaction at the template.primer site. Mol Pharmacol 1990 1.30
21 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem 2000 1.30
22 Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses. Virology 1985 1.20
23 Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. J Med Chem 1992 1.10
24 L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem 1991 1.00
25 L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother 1992 0.93
26 Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. J Med Chem 1996 0.90
27 Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. J Med Chem 1991 0.90
28 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Bioorg Med Chem Lett 2001 0.87
29 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. Bioorg Med Chem Lett 2001 0.85
30 Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge. J Med Virol 1989 0.84
31 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. Bioorg Med Chem Lett 2001 0.83
32 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg Med Chem Lett 2001 0.82
33 An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. J Med Chem 1997 0.82
34 The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors. Arch Virol Suppl 1994 0.81
35 Yeast-expressed p55 precursor core protein of human immunodeficiency virus type 1 does not elicit protective immunity in chimpanzees. AIDS Res Hum Retroviruses 1990 0.80
36 A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors. Antimicrob Agents Chemother 1993 0.80
37 In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Adv Exp Med Biol 1996 0.80
38 Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. Virology 1988 0.80
39 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. J Med Chem 1993 0.79
40 Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. J Med Chem 2000 0.79
41 Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg Med Chem Lett 2001 0.78
42 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. Bioorg Med Chem Lett 2001 0.77
43 Analysis of mRNA coding for blood-stage antigens of a rodent malarial parasite, Plasmodium yoelii: mRNA coding for a possible protective antigen purify as poly A-. J Immunol 1984 0.77
44 The immune response to poliovirus-specific synthetic peptides: effects of adjuvants and test animal species. J Virol Methods 1985 0.76
45 A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity. J Med Chem 1992 0.76
46 Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. J Med Chem 1993 0.75
47 Combinatorial synthesis of CCR5 antagonists. Bioorg Med Chem Lett 2001 0.75
48 Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library. Bioorg Med Chem Lett 2000 0.75
49 HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics. Drug Des Discov 1993 0.75